Overview of Ceftacef

Here is a quick overview of the medicine Ceftacef (active ingredient: Ceftazidime).

Property	Description
Active ingredient	Ceftazidime
Form	Powder for Solution for Injection or Infusion
Pharmacological class	Third-Generation Cephalosporin Antibiotic
General purpose	Eliminates serious bacterial infections
Origin	Semisynthetic

What Type of Antibiotic is Ceftacef (Ceftazidime)?

Ceftacef is a powerful, prescription-only semisynthetic antibiotic whose active substance is Ceftazidime. It is formally classified as a beta-lactam antibiotic and belongs to the crucial third-generation cephalosporin group. This formal classification confirms that the drug is designed to kill bacteria and treat various systemic infections. Ceftazidime is clinically recognized for its essential role in treating serious conditions such as sepsis and complicated intra-abdominal infections, often used in hospital settings.

The development of Ceftazidime represents a significant advance in pharmacology over earlier beta-lactam structures. As a semisynthetic compound, it combines a natural core with chemically enhanced components that improve its stability and effectiveness. Other products containing this formulation are known by brand names such as Fortaz and Tazicef.

Composition and Physical Form of Ceftacef

Ceftacef is a single-ingredient product supplied as a sterile Powder for Solution for Injection or Infusion containing only the active substance. This solid preparation must be reconstituted, or mixed, with a suitable base/vehicle such as sterile water or compatible intravenous fluids immediately prior to use.

This specific dosage form mandates that Ceftacef be administered solely via the parenteral administration route, typically intravenously or intramuscularly. The drug’s chemical structure is noted for its high affinity for the bacterial target, a key property in the treatment of Gram-negative pathogens. This property confirms its potent ability to swiftly eliminate bacterial sources of disease.

How Ceftacef Differs from Earlier Antibiotics

Ceftacef functions as a potent bactericidal agent, meaning it actively and irreversibly kills bacteria by directly interfering with their protective cell wall structure. Its primary distinction is a sophisticated chemical architecture that confers robust resistance against certain bacterial enzymes, specifically the beta-lactamases.

This inherent resistance allows Ceftazidime to remain active against various bacterial strains that may have developed resistance to older, less resilient cephalosporins or penicillin-class antibiotics. The drug is utilized against difficult-to-treat organisms like Pseudomonas aeruginosa, a feature that differentiates it from many other third-generation agents. The general benefit is a definitive treatment option, leveraging a highly targeted mechanism of effect to eliminate the bacterial source of the disease.

Regulatory References

U.S. National Library of Medicine (NIH/NLM)

What side effects are possible with Ceftacef?

Possible side effects and safety information

The safety profile of Ceftacef (Ceftazidime) is documented by regulatory bodies, classifying adverse reactions according to their frequency and the physiological systems affected.

Adverse Reactions Classified by System and Frequency

Adverse reactions are organized into System-Organ Classes (SOCs). Common effects (occurring in 1% to 10% of patients) typically involve Gastrointestinal Disorders (diarrhea), Blood and Lymphatic System Disorders (eosinophilia, thrombocytosis, positive Coombs’ test), and General Disorders (pain or inflammation at the injection site). Uncommon reactions include headache, dizziness, nausea, vomiting, and phlebitis.

Serious adverse reactions, though rare, are explicitly documented in regulatory labeling. These include severe Hypersensitivity Reactions (such as anaphylaxis and severe skin conditions like Stevens-Johnson syndrome) and serious Neurological Sequelae, including seizures, encephalopathy, and myoclonus (muscle twitching).

Safety Considerations for Specific Patient Groups

Regulatory documents highlight that the risk of serious neurological sequelae is significantly higher in patients with impaired renal function and in older adults if the dose is not appropriately adjusted. This is because Ceftazidime is primarily cleared by the kidneys. Additionally, individuals with a history of colitis or gastrointestinal disease require caution due to the potential for Clostridioides difficile-associated diarrhea (CDAD), which may manifest even after treatment has concluded. The concurrent use of Ceftacef with certain nephrotoxic medicinal products, such as aminoglycosides or potent diuretics, requires careful observation of renal function.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory overdose profile for this class of drug is defined by the risk of severe Central Nervous System (CNS) toxicity, particularly in the setting of impaired kidney function. Overdosage has been formally documented in patients experiencing kidney failure, which can lead to the drug accumulating in the body.

Documented Overdose Symptoms

Reactions reported in association with overdosage have included:

Seizure activity
Encephalopathy (brain dysfunction)
Asterixis (involuntary jerking movements)
Neuromuscular excitability
Coma

Emergency Response

Immediate medical help must be sought if an overdosage is suspected, even if symptoms have not yet appeared. The documented neurological reactions are severe and potentially life-threatening. Any person who receives an acute overdosage must be carefully observed and given supportive treatment by healthcare professionals.

Overdose Context

Patients with renal insufficiency are specifically noted to be at risk for overdosage and the associated severe adverse reactions. The regulatory basis for treatment states that in the presence of compromised kidney function, procedures such as hemodialysis or peritoneal dialysis may aid in the removal of the drug from the body.

Therapeutic Uses of Ceftacef

What Ceftacef Treats: Main Uses and Benefits

This medicine is commonly used across several critical therapeutic areas to address serious bacterial infections. It may be utilized as part of the clinical management when infections are severe or difficult to manage, providing support during acute episodes by addressing the underlying bacterial cause.

Ceftacef is indicated for the treatment of widespread, acute illness, including sepsis, bacterial septicemia, meningitis, and various forms of pneumonia. Its use is relevant for managing complicated infections of the abdomen, the urinary tract, and in scenarios involving hard-to-treat strains like Pseudomonas aeruginosa. Its application is focused on clinical scenarios involving heightened physiological responses and may assist with maintaining stability during periods of acute systemic imbalance.

"It is used in areas where short-term management is appropriate, especially when dealing with multidrug-resistant bacteria."

The use of Ceftacef is relevant in clinical settings involving high-risk patients, such as those with neutropenic fever, where supportive management is required to address persistent manifestations of infection. This therapeutic approach contributes to addressing symptoms related to inflammatory states and may assist with maintaining functional stability when symptoms interfere with routine activities.

Quick Fact: Supports Management of Severe Systemic Symptoms Ceftacef is primarily used in conditions marked by increased physiological stress and is relevant for managing symptoms that may become intense or disruptive in clinical settings involving acute or unstable infection patterns.

Eligibility and Restrictions for Use

Who can and cannot use Ceftacef?

Eligibility for using Ceftacef (Ceftazidime) is strictly defined by regulatory authorities based on patient profile, allergies, and organ function.

Absolute Non-Eligibility (Contraindications)

Ceftacef is strictly contraindicated for any patient with a known hypersensitivity to the active substance, Ceftazidime, or to any other medicine belonging to the cephalosporin class of antibacterial agents. Patients with a documented history of cephalosporin-associated hemolytic anemia are also prohibited from use.

Condition-Based Restrictions

Patient Group	Eligibility Status	Regulatory Requirement
Impaired Renal Function	Conditional Use	Mandatory dosage reduction is required to prevent neurological adverse reactions, as the drug is cleared primarily by the kidneys.
History of Penicillin Allergy	Use with Caution	Requires careful assessment due to the documented potential for cross-hypersensitivity reactions.
Severe Hepatic Impairment	Conditional Use	Close clinical monitoring is advised due to a lack of established safety data.

Age and Physiological Status

Ceftacef is approved for adults and children, including neonates. However, the safety and efficacy status is not established for infants 1 month of age or younger by some regulators. Use during pregnancy and lactation is permitted only when the treating professional determines the potential benefit outweighs the possible risk.

What should I know about interactions with other medicines?

Interactions with Other Medicines and Products

This section outlines documented interactions between Ceftacef and other medicines, product classes, or substances, based solely on official regulatory information. The interaction profile is structured around effects on drug exposure and physical compatibility requirements.

Documented Interaction Constraints

Official labeling identifies the following constraints and requirements:

Interacting Product Category	Official Constraint/Implication
Probenecid	Co-administration is not recommended because probenecid is documented to increase the systemic exposure (concentration in the body) of Ceftacef.
Oral Contraceptives	Use may reduce the efficacy of oral contraceptives due to effects on gut flora, which can lower estrogen reabsorption.
Drugs that Reduce Gastric Acidity	These agents may reduce the oral bioavailability of Ceftacef, potentially leading to lower-than-intended drug levels.
Calcium-Containing IV Solutions	Simultaneous administration with calcium-containing intravenous solutions (e.g., Lactated Ringer's) is prohibited due to the risk of precipitation (based on data for related cephalosporins, which often dictates a class warning).
Laboratory Tests	Ceftacef is known to interfere with certain clinical laboratory tests, requiring notification of laboratory personnel when tests are being performed.

These constraints define the necessary requirements for safe use, ensuring that co-administered agents and common procedures do not adversely affect Ceftacef's exposure or cause chemical incompatibility.

Mechanism of Action

Ceftacef is a beta-lactam antibiotic that interferes with the final stages of bacterial cell wall synthesis. The active compound covalently binds to and inactivates bacterial transpeptidases, also known as penicillin-binding proteins (PBPs), which are localized in the bacterial cytoplasmic membrane. Ceftacef acts as a structural analog of the D-Ala-D-Ala terminus of the peptidoglycan precursor chain. Binding to the active site of the transpeptidase enzyme blocks the cross-linking of the linear peptidoglycan strands, a process essential for the structural rigidity of the bacterial cell wall. This enzymatic inhibition prevents the formation of a stable, mature cell wall. The resulting loss of cell wall integrity compromises the bacterial cell's structural stability and leads to osmotic lysis and subsequent cell death in the targeted bacterial population. The mechanism is selective for bacterial PBPs and does not involve host mammalian cellular processes.

Dosage and Administration Information

How to Use Ceftacef

Ceftacef, which contains the active ingredient Ceftazidime, is an antibiotic administered exclusively by the parenteral route. This means it is delivered directly into the body, typically in a clinical or hospital setting. The medication is suitable for Intravenous (IV) injection, IV infusion, or deep Intramuscular (IM) injection.

Because the product is supplied as a sterile powder, it must be reconstituted and diluted with a compatible fluid immediately before use. When administered as an IV infusion, the process is commonly carried out over a period of 20 to 30 minutes. Once prepared, the solution generally ranges in color from light yellow to amber.

Dosing and Frequency Patterns

The standard adult intermittent dosing regimen is structured around a 1 g to 2 g dose administered every 8 or 12 hours. For severe or life-threatening infections, the usual dose is 2 g every 8 hours. In these cases, the total daily dose does not typically exceed 6 g. Administration is maintained for a specific duration determined by clinical progress, often continuing until the patient has reached a stable clinical state for at least 48 hours.

Administration Parameter	Instructions
Route	IV Injection, IV Infusion, Deep IM Injection
Standard Adult Dose	1 g to 2 g every 8 to 12 hours

Population-Specific Dosing Rules

Dosage requires reduction in adults and children with impaired kidney function. This adjustment is based on the patient's creatinine clearance because the medication is eliminated primarily through the kidneys. In such cases, an initial 1 g dose is usually provided, followed by lower maintenance doses according to the degree of renal impairment. For older adults (over 80 years of age), the daily dose should not normally exceed 3 g.

Recent Clinical Evidence

Research Evidence: Overview of Studies for Ceftacef (Ceftazidime)

The purpose of this section is to describe the types of research and clinical trials that have examined the use of Ceftacef (Ceftazidime). This evidence highlights what has been observed so far in study groups and contributes to the broader evidence landscape, but research does not determine whether an individual will respond similarly. Findings describe group patterns, not personal outcomes.

Evidence for Use in Serious Systemic Infections: Sepsis and Septicemia

Ceftacef was studied for use in acute systemic infections, including sepsis and bacterial septicemia. Researchers used randomized comparative trials and multicenter observational cohorts to explore short-term symptom changes in hospitalized patients. These studies monitored individuals with conditions associated with acute or disruptive episodes.

The research examined several outcomes related to systemic or functional imbalance, such as patient survival (e.g., 30-day all-cause mortality) and microbiological outcomes. Findings describe patterns observed in these studies when comparing Ceftacef, either alone or in combination with other agents, compared with different antimicrobial treatments. The data show patterns related to patient outcomes over defined time intervals, but long-term effects are not fully established beyond the first month after treatment.

Evidence for Use in Specific Organ-System Infections: Pneumonia and Intra-Abdominal Infections

Research examined Ceftacef in specific organ-system settings, including various forms of pneumonia and complicated intra-abdominal infections (cIAIs). These studies were relevant in trials assessing short-term or episodic symptom patterns in hospitalized patients.

For complicated intra-abdominal infections, many high-level studies were conducted using Ceftazidime in combination with a combination partner that addresses bacterial resistance. These trials monitored microbiological and clinical response rates, with findings reporting rates of clinical response at a designated follow-up visit after the treatment course was completed. Similarly, research for pneumonia monitored short-term changes and microbiological results. Much of the recent clinical evidence for both of these conditions has focused on the combination form of the drug. This means that comparative evidence remains limited for Ceftacef used as a single agent in those specific settings.

Evidence for Use in High-Risk Situations: Meningitis and Neutropenic Fever

Ceftacef was evaluated in studies focusing on episodes where symptoms become more noticeable, such as in patients with meningitis (infection of the membranes covering the brain and spinal cord) and fever in neutropenic patients (individuals with very low white blood cell counts, often due to cancer treatment).

For meningitis, evidence remains limited. Studies have primarily been pharmacokinetic studies, which research examined drug levels in the cerebrospinal fluid. Certainty remains low regarding clinical outcomes from large-scale single-agent trials for this condition. For neutropenic fever, randomized studies have monitored outcomes capturing phases of heightened symptom activity, such as the duration of fever in the observed populations. Research provides insight into short-term changes during the acute period of systemic illness.

Research Examining Use Against Difficult-to-Treat Bacteria: Pseudomonas aeruginosa

Ceftacef was studied for its activity against bacteria that may be difficult to treat, such as Pseudomonas aeruginosa. This organism was associated with severe infections, and some strains may be resistant to older antibiotics.

Laboratory research and animal models have explored the drug's properties. These studies monitored outcomes linked to inflammatory or irritative states in the presence of the specific organisms. While research highlights changes measured in the studies, the evidence is limited for Ceftacef when used alone against the most highly resistant strains, as much data now includes a combination partner for which the research was conducted.

Long-Term Research and Extended Follow-up

Research focusing on the use of Ceftacef typically emphasizes endpoints measured during the acute phase. Follow-up durations were limited in most of the acute-care trials, with observations often concluding within 30 days.

This means that there is limited information for long-term outcomes following the initial treatment phase. Studies primarily monitor patient responses over defined time intervals that cover the period of acute illness, and the long-term effects of Ceftacef are not fully established by this body of research.

What is Still Uncertain About Ceftacef’s Research Base

While research describes various treatment patterns, the evidence base still contains gaps and limitations.

For instance, the results apply only to the populations studied; for example, many studies specifically excluded patients with severe kidney problems, meaning data for that group remain insufficient. Additionally, for many complex infections, recent large-scale research primarily uses Ceftazidime in combination with another drug. This means the evidence quality varies across studies, and comparative evidence remains limited for Ceftacef used alone in certain situations. Finally, subgroup findings are uncertain for specific populations, and more research is ongoing to better understand these areas.

Frequently Asked Questions (FAQ)

Common questions about Ceftacef (FAQ)

Q: What happens if I miss a dose of Ceftacef?

Regulatory information emphasizes following the prescribed dosing schedule. Skipping doses or stopping your course too early may risk incomplete treatment of the infection and can contribute to the development of antibiotic-resistant bacteria.

Q: Is it okay to stop taking Ceftacef when I start feeling better?

Regulatory information advises patients to continue receiving the medication until the full prescribed course is completed, even if symptoms begin to improve or disappear. Stopping treatment early may result in incomplete treatment or the infection not being fully cleared.

Q: Is Ceftacef safe to take during pregnancy?

Ceftacef is assigned US FDA Pregnancy Category B. Official documents state that it should be used during pregnancy only if the potential benefit to the patient is determined to justify the potential risk to the fetus.

Q: Can mothers use Ceftacef while breastfeeding?

Official information indicates that the drug is excreted into human milk, typically in low levels. While its use is generally considered acceptable, the treating professional must weigh the known benefit to the mother against the potential risks to the infant before administration.

Q: Can Ceftacef cause thrush in babies who are breastfed?

Yes, regulatory-linked reports note that maternal use of cephalosporin antibiotics has been associated with reports of neonatal diarrhea and oral thrush in breastfed infants. Any changes in the baby's health should be observed and reported to a healthcare professional.

Q: Can I drink alcohol while taking Ceftacef?

The official adverse reactions section for Ceftacef specifically noted that no disulfiram-like reactions (a severe intolerance reaction associated with alcohol) were reported in its clinical trials. Patients with concerns about alcohol consumption should consult a healthcare professional.

Q: Does the time of day I take Ceftacef matter for its effectiveness?

The medication is dosed based on a fixed interval, such as every 8 or 12 hours, to maintain consistent drug levels in the body. Regulatory documents focus on adherence to this interval and do not specify a preferred time of day for administration.

Q: Does Ceftacef affect laboratory blood counts like white blood cells?

Official documents list certain blood and lymphatic system disorders among the common side effects. These reactions can include changes in blood counts, specifically eosinophilia (an increase in a type of white blood cell) and thrombocytosis (an increase in platelets).

Q: Can Ceftacef be taken with food?

Ceftacef is manufactured as a powder for solution and is an injectable medication administered directly into a vein (IV) or muscle (IM). Because Ceftacef is administered by injection, typical questions regarding taking oral medications 'with food' do not apply to this product.

Q: How should I store unused Ceftacef?

Official instructions state that the unreconstituted powder must be stored at controlled room temperature and protected from light. The reconstituted solution that is mixed before administration has a specific limited shelf-life and may require refrigeration depending on the exact preparation.

Q: How quickly does Ceftacef start working?

Regulatory-linked consumer information indicates that patients usually begin to notice an improvement in their symptoms during the first few days of treatment with Ceftacef.

Q: Is Ceftacef effective against the flu or common cold?

No, Ceftacef is classified as an antibiotic and works by killing susceptible bacteria. Official patient counseling information emphasizes that it is not effective against viral infections such as the flu or the common cold.

Q: What should I do if my symptoms do not improve after a few days of taking Ceftacef?

Official patient counseling states that patients should contact their prescribing professional if symptoms do not improve or worsen.

Q: Is Ceftacef generally safe for older adults?

While clinical studies did not observe overall differences in safety between older and younger subjects, regulatory information notes that greater susceptibility to drug effects cannot be ruled out in some older individuals. Dosage selection requires special care due to the potential for decreased kidney function.

Q: Is Ceftacef considered a broad-spectrum antibiotic?

Yes, Ceftacef (Ceftazidime) is classified by regulatory bodies as a third-generation cephalosporin antibiotic. This class is known for its broad-spectrum activity against various Gram-negative and Gram-positive bacteria.

Q: Is it true that Ceftacef can cause a false result on some medical tests?

The official regulatory label notes that Ceftacef is known to interfere with certain clinical laboratory tests. This requires that laboratory personnel be notified when the medication is being used and tests are being performed.

Q: Can Ceftacef affect my mood or sleep?

Regulatory documents list central nervous system effects among the rare or less common side effects reported. These can include confusion, agitation, hostility, and severe sleepiness.

Q: Does Ceftacef lower immunity?

Regulatory documents do not list general lowered immunity as a side effect. It is indicated for use in specific situations involving patients who are already immunocompromised, such as those with neutropenic fever.

Q: Is it true that Ceftacef is an 'old' antibiotic?

Ceftacef (Ceftazidime) is classified as a third-generation cephalosporin antibiotic. This classification means it belongs to a group of drugs that represents an advance in chemical structure over the earlier first- and second-generation cephalosporins.

Q: Can Ceftacef affect blood pressure or heart rate?

Regulatory documents list irregular heartbeat (tachycardia, etc.) among the less common side effects reported during clinical assessment. Specific changes to blood pressure are not prominently featured in the common side effects list.

Q: Is there a generic version of Ceftacef available, or is it only branded?

Yes, the active ingredient Ceftazidime is available in generic form from various manufacturers. It is also sold under several brand names, such as Fortaz and Tazicef.

Q: Can Ceftacef be used for skin and soft tissue infections?

Yes, official regulatory labeling lists Ceftacef as an indicated treatment for skin and skin-structure infections caused by susceptible strains of bacteria.

How should Ceftacef be stored and disposed of?

How to Store and Dispose of Ceftacef?

Ceftacef (ceftazidime) must be stored and handled according to official regulatory requirements to ensure stability and safety.

Storage Requirements

The unreconstituted powder should be stored at controlled room temperature (20 C to 25 C) and must be protected from light. The product should not be frozen and must remain in its original container. Once the powder is mixed (reconstituted), the solution has a limited shelf-life and often requires refrigeration (2 C to 8 C), depending on the concentration and diluent used. All forms of the medication must be kept out of the sight and reach of children.

Disposal Instructions

Unused or expired Ceftacef must be discarded following local requirements or official drug take-back programs. The product should not be disposed of in wastewater or flushed down a toilet.

Ceftacef